Inhibits the apoptosis-inducing activity of Fas Ligand. Binds FasL (APO-1L, CD95L, CD178).
Produktmerkmale
Extracellular domain of human Fas (aa. 7-154) fused to Fc portion of human IgG1.
Reinheit
95 % as determined by SDS-PAGE
Endotoxin-Niveau
<0.1 EU/µg purified protein as determined by LAL test.
Applikationshinweise
Functional Application: Inhibition of FAS Ligand activity in human and mouse: The apoptosis-inducing activity of FasL is inhibited by concentrations of 20-100 µg/mL of the fusion protein. Concentrations of Fas Ligand Inhibitor required to inhibit may vary depending on the cell viability and on the concentrations of sFasL used to kill the cells.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Reconstitute with 50 µL sterile water to produce a 1 mg/mL solution in PBS. Further dilutions should be made with medium containing 5% fetal calf serum (FCS) or a carrier protein.
Buffer
PBS
Lagerung
-20 °C
Target
Fas Ligand Inhibitor
Hintergrund
Fas is a 45 kDa type I transmembrane protein belonging to the TNF receptor family. Fas contains 3 cysteine-rich repeats in the extracellular portion and a cytoplasmic motif called the `death domain' (DD). Death signals are triggered upon binding to its trimeric ligand FasL which induces oligomerization of Fas. The DD associates with FADD, which in turn connects to aspartate-specific proteases (caspases) that are implicated as mediators of most types of apoptotic cell death. Synonyms: APO-1, CD95, TNFRSF 6